| [1] |
. Nat Rev Drug Discov，2018，17（3）：161.
|
| [2] |
Lee SY，Olsen P，Lee DH，et al. Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions［J］. J Immunother，2018，41（1）：19-31.
|
| [3] |
Gomes-Silva D，Mukherjee M，Srinivasan M，et al. Tonic 4-1BB costimulation in chimeric antigen receptor impedes T cell survival and is vector-dependent［J］. Cell Rep，2017，21（1）：17-26.
|
| [4] |
Mardiana S，John LB，Henderson MA，et al. A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cell［J］. Cancer Res，2017，77（6）：1296-1309.
|
| [5] |
Theocharis AD，Skandalis SS，Gialeli C，et al. Extracellular matrix structure［J］. Adv Drug Deliver Rev，2016，97：4-27.
|
| [6] |
Digre A，Singh K，Abrink M，et al. Overexpression of heparinase enhances T lymphocyte activities and intensifies the inflammatory response in a model of murine rheumatoid arthritis［J］. Sci Rep，2017，7：46229.
|
| [7] |
Foutenot JD，Gavin MA，Rudensky AY. Foxp3 porgrams the development and function of CD4+CD25+ regulatory T cells［J］. Nat Immunol，2003，4（4）：330.
|
| [8] |
Khaled YS，Ammori BJ，Elkord E. Myeloid-Deried suppressor cells in cancer：recent progress and prospects［J］. Immunol Cell Biol，2013，91（8）：493-502.
|
| [9] |
Li T，Li X，Zamani A，et al. C-Rel is a myeloid checkpoint for cancer immunotherapy［J］. Nat Cancer，2020，1（5）：507-517.
|
| [10] |
Condeelis J，Pollard JW. Macrophages：obligate partners for tumor cell migration，invasion，and metasis［J］. Cell，2006，124（2）：263.
|
| [11] |
Sharda DR，Yu S，Ray M，et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase［J］. J Immunol，2011，187（5）：2181-2192.
|
| [12] |
Baroja ML，Luenberg D，Chau T，et al. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation［J］. J Immunol，2000，164（1）：49-55.
|
| [13] |
Curran MA，Montalvo W，Yagita H，et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors［J］. PNAS，2010，107（9）：4275-4280.
|
| [14] |
Zhu C，Anderson AC，Schubart A，et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity［J］. Nat Immunol，2005，6（12）：1245-1252.
|
| [15] |
Wang L，Rubinstein R，Lines JL，et al. VISTA，a novel mouse Ig superfamily ligand that negatively regulates T cell responses［J］. J Exp Med，2011，208（3）：577-592.
|
| [16] |
Harlin H，Meng Y，Peterson AC，et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment［J］. Cancer Res，2009，69（7）：3077-3085.
|
| [17] |
Sick E，Jeanne A，Schneider C，et al. CD47 update：a multifaceted actor in the tumor microenvironment of potential therapeutic interest［J］. Br J Pharmacol，2012，167（7）：1415-1430.
|
| [18] |
Weber WP，Feder-Mengus C，Chiarugi A，et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines［J］. Eur J Immunol，2006，36（2）：296-304.
|
| [19] |
Della CM，Carlomagno S，Frumento G，et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function［J］. Blood，2006，108（13）：4118-4125.
|
| [20] |
Ye Y，Yin DT，Li C，et al. Identification of Piwil-like（PL2L） proteins that promote tumorigenesis［J］. PLoS One，2010，5（10）：e13406.
|
| [21] |
Craddock JA，Lu A，Bear A，et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b［J］. J Immunother，2010，33（8）：780-788.
|
| [22] |
Schuberth PC，Hagedorn C，Jensen SM，et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells［J］. J Transl Med，2013，11（1）：187.
|
| [23] |
Wang Y，Xu Y，Li SS，et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor engineered T cells［J］. J Hematol Oncol，2018，11（1）：60.
|
| [24] |
Fu X，Rivera A，Tao L，et al. Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels，shrink established solid tumors and increase nanoparticle delivery［J］. Int J Cancer，2013，133（10）：2483-2492.
|
| [25] |
Hosen N，Matsunaga Y，Hasegawa K，et al. The activated conformation of integrin β7 is a novel multiple myeloma-sepcific target for CAR T cell therapy［J］. Nat Med，2017，23（12）：1436-1443.
|
| [26] |
Pegram HJ，Lee JC，Hayman EG，et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning［J］. Blood，2012，119（18）：4133-4141.
|
| [27] |
Chow KPN，Qiu JT，Lee JM，et al. Selective reduction of post-selection CD8 thymocyte proliferation in IL-15Rα Deficient Mice［J］. PLoS One，2012，7（3）：e33152.
|
| [28] |
Marin V，Hoyos VM，Savoldo B，et al. In vitro and in vivo mode of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor［J］. Blood，2011，117（18）：4736-4745.
|
| [29] |
Ligtenberg MA，Mougiakakos D，Mukhopadhyay M，et al. Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity［J］. J Immunol，2016，196（2）：759-766 .
|
| [30] |
Boice M，Salloum D，Mourcin F，et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells［J］. Cell，2016，167（2）：405-418.
|
| [31] |
Holohan DR，Lee JC，Bluestone JA，et al. Shifting the evolving CAR T cell platform into higher gear［J］. Cancer Cell，2015，28（4）：401-402.
|
| [32] |
Marigo I，Zilio S，Desantis G，et al. T Cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells［J］. Cancer Cell，2016，30（3）：377-390.
|
| [33] |
Bollard CM，Rossig C，Calonge MJ，et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity［J］. Blood，2002，99（9）：3179-3187.
|
| [34] |
Gao J，Shi LZ，Zhao H，et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy［J］. Cell，2016，167（2）：397-404.
|
| [35] |
Prosser ME，Brown CE，Shami AF，et al. Tumor PD-L1 co-stimulates primary human CD8（+） cytotoxic T cells modified to express a PD1：CD28 chimeric receptor［J］. Mol Immunol，2012，51（3/4）：263-272.
|
| [36] |
Ma L，Dichwalkar T，Chang JYH，et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor［J］. Science，2019，3 65（6449）：162-168.
|
| [37] |
Amor C，Feucht J，Leibold J，et al. Senolytic CAR T cells reverse senescence-associated pathologies［J］. Nature，2020，5839（7814）：127-132.
|
| [38] |
Sachdeva M，Busser BW，Temburni S，et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality［J］. Nat Commun，2019，10（1）：5100.
|
下载:
